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ttp://dx.doi.org/10.1016/j.ajpath.2012.12.026Enterohemorrhagic Escherichia coli cause approximately 1.5 million infections globally with 176,000
cases occurring in the United States annually from ingesting contaminated food, most frequently E. coli
O157:H7 in ground beef or fresh produce. In severe cases, the painful prodromal hemorrhagic colitis is
complicated by potentially lethal hemolytic uremic syndrome (HUS), particularly in children. Bacterial
Shiga-like toxins (Stx1, Stx2) are primarily responsible for HUS and the kidney and neurologic damage
that ensue. Small animal models are hampered by the inability to reproduce HUS with thrombotic
microangiopathy, hemolytic anemia, and acute kidney injury. Earlier, we showed that nonhuman
primates (Papio) recapitulated clinical HUS after Stx challenge and that novel therapeutic intervention
rescued the animals. Here, we present detailed light and electron microscopic pathology examination of
the kidneys from these Stx studies. Stx1 challenge resulted in more severe glomerular endothelial
injury, whereas the glomerular injury after Stx2 also included prominent mesangiolysis and an eosin-
ophilic inﬂammatory inﬁltration. Both toxins induced glomerular platelet-rich thrombi, interstitial
hemorrhage, and tubular injury. Analysis of kidney and other organs for inﬂammation biomarkers
showed a striking chemotactic proﬁle, with extremely high mRNA levels for IL-8, monocyte chemo-
attractant protein 1, and macrophage inﬂammatory protein 1a and elevated urine chemokines at
48 hours after challenge. These observations give unique insight into the pathologic consequences of
each toxin in a near human setting and present potential pathways for therapeutic intervention.
(Am J Pathol 2013, 182: 1227e1238; http://dx.doi.org/10.1016/j.ajpath.2012.12.026)Supported by theNIHNational Institute of Allergy and InfectiousDiseases
grant U01AI075386 (S.K.). TheOklahomaBaboonResearch Resource at the
University of Oklahoma Health Sciences Center, from where animals were
obtained, is supported by NIH grant P40RR012317 (G. White).
Current address of J.P., Department of Comparative Medicine, University
of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.Contamination of food and water sources with Shiga toxin-
producing enterohemorrhagic Escherichia coli (EHEC) is
a global cause of sporadic outbreaks of painful diarrhea and
hemorrhagic colitis1e3 with an estimated 176,000 cases in the
United States annually and approximately one death for every
1000 infections.4,5 Symptoms arise within 3 to 4 days after
infection and most resolve, but 5% to approximately 10% of
patients progress to develop hemolytic uremic syndrome
(HUS).6 Postdiarrheal HUS is characterized by thrombocy-
topenia, nonimmune hemolytic anemia, and thrombotic
microangiopathy, often progressing to acute renal injury with
severe cases requiring renal dialysis.7 The most vulnerable to
infection are the young and elderly,8 and EHEC infections are
a leading cause of acute renal failure in otherwise healthy
children in the United States.stigative Pathology.
.EHEC bacteria attach to the intestinal epithelium with
characteristic attaching and effacing lesions, which allows
type III secretion of bacterial effector proteins and the
Shiga toxin type-1 and type-2 toxins (Stx1, Stx2) and several
variants into the host.9 Bacteremia is rare, and these toxins
are primary contributors to the development of HUS and
organ damage.10 The strain often associated with greatest
severity is the O157:H7 serotype,11 although there are dozens
of pathogenic strains. New strains are emerging with greater
Stearns-Kurosawa et alvirulence as experienced in Germany during summer 2011
when a rare enteroaggregative E. coli O104:H4 strain that
causes otherwise self-limiting diarrhea acquired both a stx2
gene and aggressive virulence.12e14 This is a matter of
considerable concern because antibiotics increase HUS
risk,15 and no toxin-speciﬁc therapies are available.
The relative contribution of the two toxins to organ injury
is difﬁcult to distinguish in patients because EHEC strains
can secrete one or both toxins in differing ratios, and the
EHEC strain may not be identiﬁed or reported. Organ injury
is assumed to be roughly equivalent between the toxins,
although postdiarrheal renal injury is more commonly
associated with EHEC strains that secrete Stx2.10 There is
suggestion that inhibition of only Stx2 is necessary for
therapeutic relief,16 but no data are available that directly
compares the toxins in an animal model that presents with
full-spectrum HUS.
In ongoing studies to develop clinically relevant EHEC
and HUS animal models, we are characterizing the patho-
physiology elicited by Stx1 or Stx2 in juvenile baboons
(Papio). We previously showed that, when the toxins are
administered intravenously, they elicit thrombocytopenia,
hemolytic anemia, thrombotic microangiopathy, and acute
kidney injury, consistent with HUS.17 Using this model, we
demonstrated rescue of the animals from an otherwise lethal
Stx2 challenge and preservation of kidney function, with
a custom-designed anti-Stx2 synthetic peptide.18 When
comparing effects of the two toxins, we observed substantial
distinguishing features, including different proinﬂammatory
responses and different timing with delayed organ injury
after Stx2 challenge. We present here detailed pathology
examinations of kidney tissue from the animals challenged
with Stx1 or Stx2 and cytokine analyses that extend our
prior characterizations of kidney injury. In the baboon
model, as in humans, the glomeruli are a particular target of
the toxins, but injury is not exclusive to that structure. Stx1
and Stx2 had distinct effects on the glomeruli, with endo-
thelial injury predominating with Stx1 and mesangial injury
a predominant feature with Stx2. Both toxins elicited
a marked chemotactic environment in the kidneys and other
organs that may contribute to the pathophysiology.
Materials and Methods
Reagents
Puriﬁed recombinant Stx2 was obtained from BEI Resour-
ces (Manassas, VA) or was purchased from Phoenix
Laboratory, Tufts-New England Medical Center Microbial
Products and Services Facility (Tufts University School of
Medicine). Stx1 was prepared from cell lysates obtained from
E. coli DH5-harboring plasmid pCKS112, which contains
the stx1 operon under the control of a thermoinducible
promoter. Stx1 was puriﬁed from cell lysates by sequential
ion-exchange and chromatofocusing chromatography. The
purity of toxins was assessed by SDS-PAGE with silver1228staining and by Western blot analysis. Prepared toxins con-
tained <0.1 ng endotoxin/mL, as determined by Limulus
amoebocyte lysate assay (Associates of Cape Cod, Inc., East
Falmouth, MA).
In Vivo Toxin Challenge Procedures
The animal studies were performed at the University of
Oklahoma Health Sciences Center animal annex with the use
of previously published procedures.17,19,20 Six- to 8-kg
juvenile baboons (Papio c. cynocephalus or Papio c.
anubis) were housed and used in accordance with approved
protocols from the Institutional Animal Care and Use
Committees and the Institutional Biosafety Committees of
Boston University School of Medicine and the University
of Oklahoma Health Sciences Center. Death is not an end-
point, and baboons were euthanized according to established
criteria if deemed necessary, before the end of the 7-day
experimental period. Animals (n Z 6 per group) were
injected i.v. with Stx1 at 10, 50, or 100 ng/kg or Stx2 at 10, 50
ng/kg on day 0. The highest toxin dose is lethal; toxin dose-
response proﬁles showing development of HUS are pub-
lished for these models.17,18 All animals received 10 mg/kg
Baytril (enroﬂoxacin antibiotic) i.m. on day 0 before toxin
challenge. Baboons then received either 3.5 mg/kg prophy-
lactic Levaquin (levoﬂoxacin antibiotic) i.v. bolus or 10 mg/
kg Baytril i.m. each day over the experimental period. Toxin-
induced hypovolemia was controlled on the basis of criteria
developed and used in previous studies.17,18,20
Histopathology
Organs were harvested at necropsy or at 7 days after chal-
lenge, and tissues were ﬁxed in 10% phosphate-buffered
formalin, embedded in parafﬁn, and sectioned. Sections of
kidney tissue were stained with H&E or PAS.
Electron Microscopy
Tissue for electron microscopy was ﬁxed in half-strength
Karnovsky solution (1% paraformaldehyde and 1.25%
glutaraldehyde in 0.1 mol/L sodium cacodylate buffer, pH
7.0). Tissue was postﬁxed in 1% osmium tetroxide for 2
hours, dehydrated in graded ethanols, and embedded in
epoxy resin. Thin sections were stained with uranyl acetate
and lead citrate and examined with a JEOL 1010 trans-
mission electron microscope (Peabody, MA). Kidney tissue
examination included at least two and usually three or more
glomeruli per animal, as well as a survey of cortical and
medullary interstitium, tubules, and blood vessels.
qPCR on Baboon Tissues
Primers for cloning baboon tumor necrosis factor-a (TNFa),
IL-6, IL-8 (CCL2), IL-12p35, macrophage inﬂammatory
protein 1a (MIP-1a CCL3), monocyte chemotactic protein 1ajp.amjpathol.org - The American Journal of Pathology
Stx, Renal Pathology, and Chemokines(MCP-1, CCL2), and vascular endothelial growth factor
(VEGF) were designed with the use of Clustal W alignments
of human, chimpanzee, and rhesus nucleotide sequences
of these cytokines. Primers were chosen on the basis of these
sequence alignments to have a Tm of approximately 55C, 12
to 18 nucleotides, and 20% to 80% guanidine and cytosine
content. Amplicons were generated from baboon cDNA
(Expand High Fidelity PCR Kit; Applied Biosystems, Foster
City, CA) and cloned into pCR4 vector with the use of the
ZeroBlunt TOPO cloning kit for sequencing (Invitrogen,
Carlsbad, CA). Sequence quality was determined from the
trace ﬁles with the use of 4 Peaks sequence analysis soft-
ware (Groothuis AGand Mekentosj B.V.; 4 Peaks, The
Netherlands). Contigs were assembled with Geneious bio-
informatics software version 4.6 (Biomatters Ltd., Auckland,
New Zealand). Baboon TNFa and IL-12p35 sequences
available in the GenBank database were used (NM_
001112648 and AY234219.1, respectively). Obtained sequ-
ences were used to design baboon-speciﬁc quantitative
real-time PCR (qPCR) primers.
Primer sets for qPCR assays were designed (Table 1) with
the use of standard parameters with the Primer3 plug-in of
Geneious bioinformatics software. Validation of assay efﬁ-
ciency and speciﬁcity for each primer set was determined by
linear regression and melting curve analysis.
Total RNA was isolated from baboon tissues stored in
RNA later. Tissues (<25 mg) were ground with a mortar
and pestle in a small amount of liquid nitrogen. Proteinase
K (20 mg/mL) was added, and samples were incubated
for 1 hour at 37C. RNA was extracted with TRIzol and
isolated (Pure link-RNA mini kit; Ambion, Carlsbad,
CA). Samples were treated with DNase, and total RNA
was quantiﬁed with nanophotometer (Implen Inc., West-
lake Village, CA). cDNA was reverse transcribed from
RNA (High-Capacity cDNA reverse transcription kit;
Applied Biosystems). qPCR of experimental samples
(tissues from 100 ng/kg Stx1, n Z 3; or 50 ng/kg Stx2,
n Z 4), healthy samples (tissues from a healthy adult
baboon), and negative controls was performed with 250
nmol/L baboon-speciﬁc and cytokine-speciﬁc primers, 2
SYBR Green Fast PCR Master Mix (Applied Biosystems)Table 1 Primers for Cytokine/Chemokine qPCR
Species Target Forward
Baboon TNFa 50-TTCAGCTGGAGAAGGG
IL-6 50-ATGCAATAACCACCCC
IL-8 50-CCTTTCCACCCCAAAT
IL-12p35 50-CCACAAAAATCCTCCC
MIP-1a 50-CCCGGTGTCATCTTCC
MCP-1 50-AAGCAGAAGTGGGTTC
VEGF 50-AGGCCAGCACATAGGA
Human IL-8 50-GGTATCCAAGAATCAG
MCP-1 50-GTCTCTGCCGCCCTTC
VEGF 50-CGAGGGCCTGGAGTGT
IL-6 50-TCAGATTGTTGTTGTT
b-actin 50-CCTGGCACCCAGCACA
The American Journal of Pathology - ajp.amjpathol.orgwith the use of a StepOne Plus system (Applied Bio-
systems). Reactions were cycled as follows: 95C for 5
minutes, then 40 cycles of 95C for 1 second followed by
60C for 3 seconds. To ensure speciﬁcity, a melting curve
analysis was performed with each run. Quantitation was
based on standards from dilutions of human DNA along
with human glyceraldehyde-3-phosphate dehydrogenase
primers in each test run. Ct values were obtained with
StepOne software, and a standard curve was plotted with Ct
versus DNA concentration. The Ct values of test samples
were extrapolated, and the amount of RNA was expressed
as ng/mg total RNA. Fold change in the expression of each
cytokine was calculated relative to untreated (healthy)
sample values.
Cell Culture
Primary human renal glomerular endothelial cells (Cascade
Biologics, Portland, OR) were grown in EC medium with
endothelial cell growth supplement (ScienCell, Carlsbad,
CA) on tissue culture plates coated with 0.1% gelatin. Cells
(passages 2 to 5) were incubated with 400 ng/mL Stx1 or Stx2
for 24 hours (>90% viable). Total RNA was isolated with
RNAqueous Kit (Applied Biosystems). RNA was reverse-
transcribed into cDNA with the use of QuantiTect Reverse
Transcription Kit (Qiagen, Valencia, CA). qPCR reactions
were run with the fast SYBR Green master mix (StepOne
Plus; Applied Biosystems) according to the manufacturer’s
protocol. Data analyses were performed with StepOne Soft-
ware 2.0 (Applied Biosystems). The ratio of mRNA was
calculated by the comparative threshold cycle method with b-
actin (ACTB) as control. Primers for each human cytokine
gene were designed with Primer Express 3.0 (Applied Bio-
systems); primer sequences can be found in Table 1.
Cytokine Biomarker Analyses
Cytokine protein levels were quantiﬁed by xMAP multiplex
ﬂuorescent bead-based assays with the use of a Luminex
200 IS system (Millipore, Billerica, MA), Luminex
xPONENT software version 3.1 (Luminex, Austin, TX),Reverse
TGAT-30 50-CCAAAGTAGACCTGCCCAGA-30
TGAA-30 50-CTGCAGCCACTGGTTCTGT-30
TTATC-30 50-TTCTGTATTGACGCAGTGTGG-30
TTGA-30 50-CCGAATTCTGAAAGCATGAAG-30
TAAC-30 50-CCACTCCATACTGGGGTCAG-30
AGGA-30 50-AGGCTTCGGAGTTTGGATTT-30
GAGA-30 50-CCTCGGCTTGTCACATTTTT-30
TGAAGA-30 50-CTACAACAGACCCACACAATA-30
TGTG-30 50-AGGTGACTGGGGCATTGATTG-30
GT-30 50-CCGCATAATCTGCATGGTGAT-30
AATGG-30 50-TAGTGTCCTAACGCTCAT-30
AT-30 50-GCCGATCCACACGGAGTACT-30
1229
Stearns-Kurosawa et aland nonhuman primate cytokine panel kits (Millipore) as
described previously.17 For each sample, median ﬂuorescent
intensity was analyzed with a weighted ﬁve-parameter
logistic (Milliplex Analyst; Millipore) and quantiﬁed rela-
tive to the standard curve for that cytokine. Student’s t-test
was used to determine statistical differences between toxins
and from time zero (T0) values.Figure 1 Kidneys from Stx1-challenged animals show dose-dependentResults
Previously, we showed that challenge of baboons with Stx1
or Stx2 elicited shared and distinct effects in a dose-
dependent manner.17 Both toxins elicited the spectrum of
clinical manifestations, characteristic of HUS, including thro-
mbocytopenia, thrombotic microangiopathy, and acute renal
injury with progression to renal failure. Detailed pathologic
examinations are presented here, with a focus on the kidneys
as a primary target organ of the toxins.injury of the glomerular ﬁltration barrier and tubules. Light microscopic
images shown represent the most severe changes seen at each dose. Stx1
dose indicated at left for each row. Scale bars (for each column): 50 mm
(G); 100 mm (H); 0.5 mm (I). A, D, and G: PAS-stained kidney cortex.
Glomeruli show a membranoproliferative pattern of injury at higher doses
of Stx1, with increased lobularity, capillary wall thickening and double
contouring, loss of capillary lumens, mild mesangial expansion, and focal
hypoperfusion. Proteinaceous debris is seen in Bowman’s space at higher
doses. B, E, and H: H&E-stained kidney cortex shows features of acute
tubular injury at higher doses of Stx1, including tubular luminal distension
and epithelial ﬂattening. Focal protein reabsorption is also present in
tubular epithelia. C, F, and I: H&E-stained kidney tissue. Medullary columns
show increasing proportion of distal tubules occluded with proteinaceous
casts, with increasing Stx1 dose. Vasculature (arterial and venous) showed
no signiﬁcant pathologic changes.Stx1 Induces Severe Glomerular Endothelial Injury
Kidneys from 13 Stx1-challenged animals (three at 10 ng/kg;
ﬁve at 50 ng/kg; and ﬁve at 100 ng/kg) were examined by
light microscopy. Light microscopic changes in the kidneys
from Stx1-challenged animals were characteristic of severe
injury of the glomerular ﬁltration barrier with dose-
dependent severity. In the low-dose (10 ng/kg) Stx1
animals, only mild/minor changes were observed in the glo-
meruli, including mild glomerular hypertrophy (three of three
animals), mild mesangial expansion (two animals), or mild
glomerular hypoperfusion (one animal). No signiﬁcant pat-
hologic changes were observed in the tubulointerstitium
or vasculature (Figure 1, AeC; Table 2). More substantial
pathologic changes were observed in animals exposed to
higher doses of Stx1 (50 ng/kg, Figure 1, DeF; 100 ng/kg,
Figure 1, GeI). The changes were similar in nature and
severity for both doses.
The glomeruli in most of the high-dose Stx1 animals
showed changes characteristic of a membranoproliferative
pattern of injury, including mild mesangial expansion and
increased lobularity of the tuft (seven animals), glomerular
basement membrane (GBM) thickening (six animals), and
mild-to-moderate double contouring (six animals) (Figure 1,
D and G). Focal glomerular hypoperfusion was noted in six
animals. All animals in the high-dose groups showed at least
one of the above described glomerular pathologic changes at
the light microscopic level. Proteinaceous or granular debris
was often seen in Bowman’s space of glomeruli in all high-
dose animals, regardless of whether the involved glomeruli
showed other pathology.
Changes in the tubules were more consistent among the
high-dose animals and included mild tubular injury (nine
animals), proteinaceous cast formation in distal tubules
(nine animals), most notable in the medullary columns, and
focally prominent tubular epithelial protein reabsorption1230(nine animals) (Figure 1, E and H). Focal mononuclear and/
or polymorphonuclear interstitial inﬂammation was obs-
erved in two high-dose Stx1 animals. Aside from mild
arterial and arteriolar sclerosis seen in two high-dose Stx1
animals, the vasculature (arterial and venous) in Stx1-treated
animals showed no signiﬁcant pathologic changes (Figure 1,
F and I).
Stx2 Induces Glomerular Injury and Mesangiolysis
Kidneys from 11 Stx2-challenged animals (four at 10 ng/kg;
seven at 50 ng/kg) were examined by light microscopy.
Compared with Stx1-challenged animals, Stx2-challenged
animals exhibited pathologic changes in the kidney, indic-
ative of severe acute tubulointerstitial injury, including
hemorrhage, with less obvious glomerular changes at the
light microscopic level (Figure 2 and Table 2). One imp-
ortant exception was that kidneys of animals challenged
with Stx2, including one of four low-dose and all high-dose
Stx2-challenged animals, exhibited extensive, usually dif-
fusemesangial cell pyknosis (Figure 2, A andD). This ﬁnding
was not seen in Stx1-challenged animals. Otherwise, kidneys
from three of four low-dose Stx2 animals showed mildajp.amjpathol.org - The American Journal of Pathology
Table 2 Light Microscopic Findings after Challenge with Stx1 or Stx2
Glomeruli Tubulointerstitium
Toxin Dose (ng/kg) Survival (h)
Endocap
inﬁl
Mesangial
apoptosis
Mesangial
mitosis Distension
Epithelial
ﬂattening
Tubular
pyelo. (poly)
Interstit
hemor
Tubular
epithelial
prolif./mitoses
Stx1 10 168* 0 0 0 0 0 0 0 0
10 168* 0 0 0 0 0 0 0 0
10 168* 0 0 0 0 0 0 0 0
50 58 0 0 0 1 1 0 0 0
50 72 0 0 0 1 1 0 0 0
50 72 0 1 0 1 1 0 0 0
50 74 0 0 0 1 1 2F 0 0
50 168* 0 0 0 0 0 0 0 0
100 48 0 0 0 1 1 0 0 0
100 49.5 0 0 0 1 1 0 0 0
100 57.5 0 0 0 2 2 0 0 0
100 60 0 0 0 1 1 0 0 0
100 72 0 0 0 2 2 0 0 0
Stx2 10 111.2 0 3 0 1 1 2F 3 0
10 288* 0 0 0 0 0 0 0 0
10 672* 0 0 0 0 0 0 0 0
10 720* 1F(1) 0 0 0 0 0 0 0
50 84 0 1FS 0 1 1 0 2y þ/
50 96 0 2 1 1 0 0 2y 0
50 96 0 0 0 0 0 1F 0 0
50 112 0 4 0 2 2 0 4þ 3
50 121.6 0 4 0 2 2 1F 4þ 2
50 121.3 0 4 0 2 3 0 4þ 4þ
50 128 0 3 0 2 2 1F 1F 2
Categories scored: þ/ (occasional), 0 to 4þ where 0 Z not observed and 4þ Z most severe.
*Time at necropsy of survivor (survivor is 168 hours).
yMedulla only.
F, focal (otherwise diffuse); S, segmental (otherwise global).
Stx, Renal Pathology, and Chemokinesglomerular pathology, including mild mesangial expansion
(three of four), segmental double contour formation (two of
four), and GBM thickening (one of four).
Similar changes were seen in glomeruli of high-dose Stx2
animals. Mild mesangial expansion was observed in all six
high-dose Stx2 animals, whereas three animals exhibited
focal glomerular hypertrophy, two showed segmental double
contour formation, and two exhibited GBM thickening. Two
high-dose Stx2 animals also showed focal glomerular hyp-
operfusion. Isolated mitotic ﬁgures were observed in the
mesangium in one high-dose Stx2 animal.
The tubulointerstial changes in Stx2-challenged animals
appeared to exhibit a greater degree of dose dependence
than did the glomerular changes. Only one of the low-dose
Stx2 animals showed signiﬁcant tubulointerstitial pathology,
whereas all of the high-dose Stx2 animals showed signiﬁ-
cant changes. The involved kidneys showed features of tu-
bular injury, including mild-to-moderate tubular distension
and epithelial ﬂattening; focal tubular epithelial protein
reabsorption was also seen in the same specimens (Figure 2,
B and E). Four of the six high-dose Stx2 animals also sho-
wed tubular regenerative changes, including numerous
epithelial cell mitotic ﬁgures. Scattered proteinaceous castsThe American Journal of Pathology - ajp.amjpathol.orgwere observed in one low-dose and four high-dose Stx2
specimens.
One low-dose and ﬁve high-dose Stx2 animals showed
extensive interstitial hemorrhage that extended into the
medulla in some cases (Figure 2, B, C, E, and F). Focal
tubulointerstitial inﬂammation, often with a prominent eosi-
nophilic inﬁltrate, was noted in three low-dose and four high-
dose Stx2 specimens. Mild arterial and arteriolar scleroses
were seen in the kidneys of one low-dose and four high-dose
Stx2 animals.
Electron Microscopic Findings after Stx1 or Stx2
Kidney tissue from one high-dose (50 ng/kg) Stx1-
challenged animal was available for examination by elec-
tron microscopy. The glomeruli in this animal showed
features of severe endothelial injury at the ultrastructural
level, including diffuse endothelial cell swelling and loss of
fenestrations, extensive detachment of the endothelial cells
from their basement membranes, focal endothelial denuda-
tion, and platelet thrombus formation and ﬁbrin activation in
numerous capillary loops (Figure 3, AeC). Other structures
in the glomeruli, including the podocytes, GBM, and1231
Figure 2 Kidneys from Stx2-challenged animals show interstitial
hemorrhage, inﬂammation, and mesangiolysis. Light microscopic images
shown represent the most severe changes seen at each dose; features
described were seen in a subset of low-dose specimens and all high-dose
specimens. Stx2 dose indicated at left for each row. Scale bars (for each
column): 50 mm (D); 100 mm (E); 0.5 mm (F). A and D: PAS-stained kidney
cortex. Glomeruli show mild mesangial expansion and widespread mesangial
cell pyknosis and karyorrhexis (arrows). There is also segmental thickening of
glomerular capillary walls, and focal inﬂammatory cell margination. B and E:
H&E-stained kidney cortex show features of focal acute tubular injury, focal
interstitial hemorrhage, and focal interstitial inﬂammation with many
eosinophils, more prominent at higher doses of Stx2. Focal protein reab-
sorption is also present in tubular epithelia. C and F: H&E-stained kidney
tissue. Renal medullary columns show extensive interstitial hemorrhage.
Vasculature showed no signiﬁcant pathologic changes.
Stearns-Kurosawa et almesangium, did not show signiﬁcant pathologic changes.
The peritubular capillaries also exhibited signs of severe
endothelial injury, including diffuse swelling of endothelial
cells, focal endothelial denudation, focal ﬁbrin activation,
and occasional marginating inﬂammatory cells (Figure 3D).Figure 3 Electron microscopy of kidney tissue from a Stx1-challenged
animal shows acute endothelial injury and platelet thrombus formation.
Tissue from a Stx1-challenged animal was available for examination by
electron microscopy. A: Typical glomerular segment shows thrombosis and
occlusion of capillary loops and accumulation of proteinaceous ﬂuid in
Bowman’s space. B: Capillary loop segment with endothelial loss and ﬁbrin
accumulation (arrow). Podocyte foot processes are intact. C: Capillary loop
occluded by swollen cells, platelets, and ﬁbrin. D: Peritubular capillary
exhibiting endothelial cell swelling, focal endothelial denudation (arrow-
heads), focal ﬁbrin activation (arrow), leukocyte margination, and blood
ﬂow stasis. Scale bars: 4 mm (A and D); 1 mm (B); 2 mm (C).
1232Mild features of endothelial injury were also noted in arteri-
oles, including mild endothelial swelling and focal inﬂam-
matory cell margination. The tubules exhibited features of
focal injury, including vacuolization, loss of brush border,
and cell debris in some tubular lumens. Focal tubular
epithelial protein reabsorption was also seen, as represented
by the presence of electron dense lysosomes in tubular
epithelial cells.
Kidney tissue from ﬁve animals challenged with Stx2,
including one animal challenged with 10 ng/kg and four
animals challenged with 50 ng/kg Stx2, were examined by
electron microscopy. The animal challenged with 10 ng/kg
Stx2 showed no signiﬁcant pathologic changes in the kidney
at the ultrastructural level. However, kidneys from all of
the high-dose Stx2-challenged animals (Figure 4, AeD)
showed features of moderate-to-severe glomerular endo-
thelial injury, including cell swelling and loss of fenestra-
tions, focal and segmental cell detachment, widening of the
subendothelial space, and subendothelial accumulation of
loose granular material. In one instance, a mitotic ﬁgure was
observed in a glomerular endothelial cell. The endothelial
changes were accompanied by mild and focal GBM irregu-
larities, including isolated segmental basement membrane
redundancy (double contours) in three of four animals. FocalFigure 4 Electron microscopy of kidneys from Stx2-challenged animals
show acute endothelial injury and mesangial apoptosis. Kidney tissues from
four animals challenged with 50 ng/kg Stx2 were examined by electron
microscopy. A: Glomerular segment, typical of all specimens examined,
shows features of endothelial injury, including cell swelling and loss of
fenestrations. Podocyte foot processes show mild morphologic irregularity
but do not exhibit outright effacement. A pyknotic mesangial cell is noted
at lower right. B: Mesangial area shows dissolution of the mesangial matrix
(mesangiolysis) and mesangial cell pyknosis and karyorrhexis (arrows).
C: Capillary loop at left shows endothelial cell swelling, detachment, and
segmental denudation. A platelet thrombus is attached to the endothelial
surface (arrow). Podocytes show mild foot process irregularities, micro-
villous degeneration, and electron dense lysosomes (protein reabsorption
granules), indicating protein loss through the glomerular barrier. D: Peri-
tubular capillary at top of image shows endothelial cell swelling and mitosis
(arrow). Endothelial vacuolization and leukocyte margination is also
evident. Red blood cells are scattered throughout the loose, edematous
connective tissue of the interstitium, indicative of interstitial hemorrhage.
Scale bars: 4 mm (AeD).
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Table 3 Renal Interstitial Inﬂammatory Cell Inﬁltrates
Toxin Dose ng/kg (No.) Survival, average hours (range) Mono (Range, 0e4) Poly (Range, 0e4)
Stx1 10 (3) 168* 0 (0) 0 (0)
50 (5) 69 (58e168) 0.20 (0e1F) 0.6 (0e2FE)
100 (5) 57.4 (48e72) 0 (0) 0 (0)
Stx2 10 (4) 153.8 (111e168) 1.5 (0e2F) 1.0 (0e2FE)
50 (7) 108.4 (84e128) 0.42 (0e2F) 1.3 (0e2FE)
*Animal survived to day 7 (necropsy at approximately 168 hours).
E, inﬁltrate includes eosinophils; F, focal (otherwise diffuse); Mono, mononuclear; Poly, polymorphonuclear.
MCP-1
IL-8
Stx, Renal Pathology, and Chemokinesplatelet microthrombus formation was noted in glomerular
capillary loops of two high-dose Stx2-challenged animals.
In each of the ﬁve high-dose Stx2 animals, the mesangial
areas showed various amounts of mesangiolysis, character-
ized by replacement of mesangial matrix with loose granular
material. Three high-dose animals showed various degrees,
ranging from focal to diffuse, of mesangial cell pyknosis and
karyorrhexis, characteristic of apoptosis.
Although podocytes in low-dose Stx2 animals showed no
pathologic changes, in all high-dose animals, the podocytes
showed features of mild injury, including scattered foot
processes with irregular appearing cross sections (with little
or no effacement per se) in four animals, mild microvillous
degeneration in three animals, and focal protein reabsorption
in one animal; the latter indicative of protein loss through
the glomerular barrier.
Peritubular capillaries in all high-dose Stx2 animals sho-
wed a variable extent of endothelial injury, with focal mild-to-
diffuse moderate endothelial swelling and vacuolization,
associated with focal blood ﬂow stasis. Focal thrombosis and
inﬂammatory cell margination were also noted within peri-
tubular capillaries in three of four high-dose Stx2 animals. In
one high-dose animal, a mitotic ﬁgure was noted in a peri-
tubular capillary endothelial cell (Figure 4D). High dose
animals also showed generally mild interstitial inﬂammation
and hemorrhage. Minimal endothelial injury was observed in
arterioles. Focal tubular injury was observed in all high-dose
animals, with epithelial ﬂattening, vacuolization, and/or loss
of brush border noted in scattered tubules.Figure 5 Eosinophilic inﬂammatory inﬁltrates after Stx1 challenge.
Kidney tissue from an animal challenged with 50 ng/kg Stx1 (euthanized at
168 hours after challenge) was examined by light microscopy after H&E
staining. Black boxes: perivascular inﬁltrates with a predominance of
eosinophils. White box: PMN inﬁltrates.
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Animals challenged with either Stx1 or Stx2 showed
considerable inﬂammatory cell margination of mononuclear
and polymorphonuclear inﬂammatory cells (Table 3), some
of which were eosinophilic (Figure 5). This suggests the
activation of leukocyte recruitment mechanisms.
To evaluate this further, mRNA levels for several com-
mon cytokines and chemokines were determined with tis-
sues obtained at necropsy from experimental animals (100
ng/kg Stx1, n Z 3; 50 ng/kg Stx2, n Z 4) and baboon-
speciﬁc primers. Data were normalized for values obtained
with tissues from a healthy baboon. In the kidneys, high
levels of mRNA were found for chemokines IL-8 (CXCL8),
MCP-1 (CCL2), and (MIP-1a (CCL3) from animals chal-
lenged with high-dose Stx1 or Stx2 (Figure 6). Stx2 (mean,
861.1; range, 148.7 to 1562.0) increased VEGF mRNA
levels signiﬁcantly higher than Stx1 (mean, 5.7; range, 0.07
to 16.2; P < 0.05). In comparison, changes in mRNA for
the inﬂammatory cytokines TNFa and IL-12p35 were
modest, and no differences were observed between Stx1 or
Stx2 challenge.
Stored tissues suitable for quantiﬁcation of cytokine/
chemokine protein were not available to conﬁrm protein0 20 40 60
IL-6
VEGF
TNFa
IL-12p35
MIP-1a
2000 4000 6000 8000
Fold increase  (Kidney)
Figure 6 Chemokine mRNA is highly up-regulated in kidneys after Stx1
or Stx2 challenge. Baboon kidney tissues obtained at necropsy after
challenge with 100 ng/kg Stx1 (black) or 50 ng/kg Stx2 (striped) were
processed to obtain total RNA, then cDNA was generated, and qPCR was
performed for each mediator shown as described in Materials and Methods.
Data were normalized to values obtained from normal healthy baboon
kidney tissue to obtain fold increase. Data shown are means  SD obtained
from multiple animals (Stx1, n Z 3; Stx2, n Z 4).
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Stearns-Kurosawa et alproduction from the increased mRNA levels, but timed
urine samples were part of the original experimental design
to characterize pathophysiology of Stx challenge. Urine
samples from the same animals as those presented here for
pathologic examination were tested for cytokine/chemokine
protein levels. Timed samples showed increases in urine
chemokines within 24 to 48 hours after toxin challenge
(Figure 7A). Compared with urine collected at T0 just
before toxin injection (Figure 7B), most biomarker levels
shown were signiﬁcantly elevated at 48 hours after chal-
lenge with either toxin (IL-6, P < 0.01; IL-8, P < 0.05;
MCP-1, P < 0.00001; VEGF, P < 0.001). Urinary MIP-1a
levels did not change, and TNFa was below detection
limits. When comparing differences between the toxins,
urinary VEGF (P < 0.01) and proinﬂammatory IL-6 lev-
els (P < 0.05) were higher after Stx1 at 48 hours after
challenge. Stx1 induces a more rapid inﬂammatory response
and time to euthanasia compared with Stx2 challenge in the
baboon models.17
To conﬁrm Stx ability to increase chemokine mRNA
expression, human renal microvascular endothelial cells
were incubated in vitro with either toxin for 24 hours
(>95% viability). Stx1 or Stx2 increased IL-8 mRNA
expression levels 50-fold to w70-fold, but there was little
effect of either toxin on MCP-1 or VEGF (Figure 8).
Biomarker mRNA levels were similarly quantiﬁed by
qPCR in tissue samples from other organs taken at necropsyFigure 7 Urine chemokine levels increase after Stx challenge. A: Urine obtained
50 ng/kg Stx2) was analyzed for biomarkers with the use of multiplex immunoassa
shown. B: Urine biomarkers at T0 just before toxin (X) or at 48 hours after toxin f
*P < 0.05, **P < 0.01. IL-8, squares; MCP-1, upward pointing triangles; MIP-1a,
1234from these animals for comparison (Figure 9). Overall, the
changes were similar to that observed in the kidneys, albeit
to a lesser degree. Up-regulation of mRNA levels for IL-8,
MCP-1, and more variably for MIP-1a, was observed in
small intestine, colon, lung, and spleen. Modest or minimal
changes were observed for IL-12p35 and TNFa in these
organs with no consistent differences elicited by Stx1 or
Stx2.Discussion
The development of HUS and acute kidney injury after
infection with Shiga toxin-producing E. coli is a clinically
important complication associated with increased risk of
patient morbidity and mortality. The present study presents
a detailed pathologic examination of the changes induced in
kidneys as a consequence of Stx1 or Stx2 in an animal
model that replicates the HUS manifestations observed in
patients during EHEC infection. Our primary observations
are that the pattern of glomerular and tubulointerstitial
injury differed between the two toxins in our baboon models
and that challenge with the toxins elicits leukocyte chemo-
tactic responses in kidney and other tissues that may con-
tribute to the pathophysiology.
Glomerular injury after Stx1 challenge featured prominent
HUS-like capillary wall changes, including thickening of theat the indicated time points after high-dose Stx challenge (100 ng/kg Stx1 or
ys as described in Materials and Methods. Mean values from ﬁve animals are
rom individual animals. Student’s t-test, difference between Stx1 and Stx2.
downward pointing triangles; VEGF, diamonds; IL-6, circles.
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Figure 8 Chemokine mRNA expression in cultured renal endothelial
cells. Human microvascular renal endothelial cells were incubated for 24
hours with 400 ng/mL Stx1 (black) or Stx2 (striped). cDNA was reverse
transcribed from total RNA preparations and qPCR was performed with
biomarker-speciﬁc primer pairs. The mRNA ratio was calculated by the
comparative threshold cycle method with b-actin (ACTB) as control. Values
are means  SD of triplicate wells.
Stx, Renal Pathology, and ChemokinesGBM and double contouring with prominent thrombus
formation, and severe endothelial injury with diffuse cell
swelling and focal endothelial denudation. Podocytes did not
appear to be injured after Stx1, but after Stx2 podocytes
showed features of mild injury at the ultrastructure level. In
patients, the renal pathology as a consequence of EHEC
infection includes cortical necrosis, glomerular thromboses,
and congestion with widened subendothelial space, endo-
thelial cell swelling, neutrophilia, and occasional mesan-
giolysis.21,22 We also observed these consequences with the
toxins, although mesangiolysis and interstitial hemorrhage
were more predominant after Stx2.
Stx1 induced only mild mesangial swelling, in contrast to
the prominent loss of mesangial cells after Stx2. Mesangial
cells provide structural support for glomerular capillary
loops, but also have metabolic functions by generating0 20 40 60
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IL-12p35
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The American Journal of Pathology - ajp.amjpathol.orga unique mesangial matrix, contributing to regulation of
glomerular capillary ﬂow and ultraﬁltration, and providing
growth factors. The loss of mesangial cells can be preceded
by damage to glomerular endothelial cells and loss of
platelet-derived growth factor B, which is an essential
mesangial survival factor. Glomerular endothelial dysfunc-
tion in other diseases, such as diabetic nephropathy23 or
Plasmodium vivax malaria,24 often correlates with throm-
botic microangiopathy, glomerular capillary microaneu-
rysms, and mesangiolysis. The severe glomerular endothelial
injury in Stx1 animals, but selective mesangiolysis in Stx2
animals, suggests that other mechanisms may contribute; but
there is sufﬁcient overall cellular damage to impair glomer-
ular function during development of HUS.
Renal inﬂammatory cell inﬁltrates observed more fre-
quently after Stx2 challenge included a surprising number
of eosinophils. Clinical eosinophilia (>6% of total white
blood cell count) is reportedly a common ﬁnding in renal
diseases with the highest correlation in patients with vascular
disease (diabetes, hypertension, cholesterol emboli) and no
association with allergies or fungal or parasitic infections.25
Eosinophilia is not observed in baboon Stx models,17 and
IL-5, which induces eosinophil maturation from CD34þ
precursor cells, is not elevated in the studied models (data not
shown). However, eosinophilia was observed in Dutch belted
rabbits challenged with EHEC O157:H7,26 and eosinophilic
inﬁltration of the lamina propria accompanied severe intes-
tinal damage of piglets after gastric challenge with a Stx2e-
producing EHEC strain.27 Kidney eosinophil inﬁltration
is also an independent predictor of severe renal dysfunction
in patients with autoimmune antineutrophil cytoplasmic
antibody-associated vasculitis,28 but there is little pathologic
data available to describe a presence of eosinophils in kidneys
of patients with EHEC infections. We cannot rule out the
presence of a coinfection that contributed to the predomi-
nance of eosinophils, but the baboons used in the present
study are screened routinely for viral and parasitic infections1000 1500
  (Colon)
1000 1500
 (Spleen)
Figure 9 Chemokine mRNA increases in
multiple baboon organs. Small intestine, colon,
lung, and spleen tissue samples obtained at
necropsy after challenge with 100 ng/kg Stx1
(black) or 50 ng/kg Stx2 (striped) were processed
to obtain total RNA for generation of cDNA and
qPCR for each mediator shown as described in
Materials and Methods. Data were normalized to
values obtained from normal healthy baboon
kidney tissue to obtain fold increase. Data shown
are means  SD obtained from multiple animals
(Stx1, n Z 3; Stx2, n Z 4).
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Stearns-Kurosawa et aland were clinically healthy.29 This was not observed after
Stx1 challenge or low-dose Stx2, and we have not observed
eosinophilic inﬁltration in baboon kidneys after other infec-
tious challenges otherwise.19,20,30 It is also possible that
eosinophilic inﬁltration after Stx2 is a feature of the baboon
toxin model and not of human EHEC infection. Eosinophils
may contribute to the thrombotic microangiopathy by pro-
moting a procoagulant environment. Although controversial,
one study showed that eosinophils have high concentrations
of active tissue factor, the in vivo initiator of coagulation.31 It
is possible that this tissue factor is from monocyte contami-
nation or acquired passively from other cells,32 but other
eosinophil products such as eosinophil peroxidase could
contribute to cellular oxidation and inﬂammation, both of
which are procoagulant.33
The presence of urine chemokines and increased che-
mokine mRNA in kidney tissue after Stx challenge is
consistent with the leukocyte inﬁltration observed by path-
ologic examination of the baboon kidneys. Challenge with
a high dose of either toxin resulted in increased chemokine
mRNA levels in the kidneys and urinary protein levels,
particularly IL-8 (CXCL8), MCP-1 (CCL2), and MIP-1a
(CCL3). The cell source of the kidney and urine chemokines
is difﬁcult to identify in these animals, but our in vitro data
suggest that at least renal glomerular endothelial cells are
not a likely source of MCP-1 after Stx challenge. This
chemotactic environment would favor inﬂux of activated
leukocytes that may carry toxin and impose collateral
leukocyte-mediated cell injury. MCP-1 attraction of acti-
vated monocyte-expressing procoagulant tissue factor could
contribute to development of thrombi. EHEC patient neu-
trophils stain for Stx antigen,34 and kidney IL-8 may recruit
activated neutrophils that carry toxin from the intestinal
epithelia for deposition at the glomerular endothelium.35,36
Other studies have shown that the chemokine receptors
CXCR4 and CXCR7 with lymphotactic ligand CXCL12
(stromal cell-derived factor-1) contribute to Stx injury
of microvascular endothelial cells and are pathogenic in
murine Stx2 models.37 Cultured microvascular endothelial
cells treated with Stx2 released CXCL12 ligands, and Stx2
increased expression of platelet P-selectin38 which could
contribute to thrombotic microangiopathy. Collectively, the
prediction is that targeted inhibition of IL-8 or other che-
mokines may prevent EHEC-HUS or may reduce disease
severity, and these studies are in progress.
The outcome after challenge with either toxin is acute
kidney injury, but we consistently observe differences in
host responses elicited between the two toxins, either tissue
pathology or inﬂammation markers. Mechanisms that could
account for these differences may lie in structural differ-
ences between the toxins, receptor heterogeneity, and/or
receptor microenvironment in a particular tissue. The pro-
totype Stx1 and Stx2 molecules are only 56% identical at
the amino acid level, and each has multiple variants that are
associated with differing degrees of clinical disease.39 Tar-
geted loss of the Gb3 glycosphingolipid receptor (CD77)1236results in resistance to Stx intoxication in mice,40 but in vivo
susceptibility during infection is likely governed by more
subtle mechanisms. Both toxins bind to Gb3 with similar
speciﬁcity, but the Stx1 interaction has a 10-fold higher
afﬁnity and the Stx2 interaction has a slower off-rate.41 A
related glycolipid, Gb4, has high afﬁnity for the Stx2e
variant to cause edema in a piglet model but little afﬁnity for
other Stx2 molecules.42 There is also heterogeneity in the
fatty acyl chains of Gb3 with respect to chain length and
degree of unsaturation that contributes to differential toxin
binding and intracellular effects.43,44 Variability in receptor
expression and density on endothelial cells is well known,
either in vitro with degree of cell conﬂuence, or in vivo with
respect to vascular bed45 and presence of inﬂammatory
signals such as TNFa.46 In an earlier model of baboon Stx1
toxemia, preconditioning the animal with lipopolysaccha-
ride up-regulated toxin receptor expression in kidneys and
increased Stx1-mediated disease severity.47 Finally, these
glycolipid toxin receptors are enriched in lipid rafts of
caveolae, which are plasma membrane microenvironments
that support receptor avidity, signaling, and intracellular
toxin trafﬁcking.48,49 Additional studies with isolated bab-
oon glomerular endothelial cells and tubular epithelial cul-
tures are necessary to identify contributions of receptor
heterogeneity and toxin binding kinetics to differential toxin
responses.
Priming of the Stx system with lipopolysaccharide (endo-
toxin), TNFa, or ADP potentiates toxin chemotactic and
inﬂammatory responses in vitro and in vivo,50e52 but the
relevance to disease pathogenesis in patients is not clear.
Addition of lipopolysaccharide priming to Stx2 challenge
in mice will induce thrombocytopenia,51 but this cause
is disseminated intravascular coagulation53,54 rather than
HUS, and they have different coagulation proﬁles. To
investigate pathophysiology induced by only the toxins, we
made signiﬁcant effort to reduce endotoxin contamination.
Like humans, baboons respond to endotoxin with early
increases in TNFa and other inﬂammatory cytokines.55 Lack
of detectable TNFa protein in blood17,56 or urine of our Stx-
challenged baboons is consistent with our effort to monitor
only responses to Stx.Under these conditions,we consistently
observe a modest proinﬂammatory response to the toxins17
and development of a robust chemotactic environment.
Limitations of this study include that these are nonhuman
primates receiving toxins, not enteric bacterial infection, so
correlates with natural EHEC infection are limited, and the
toxin doses are likely higher than that experienced by
patients. We also observed discrepancy between tissue
mRNA and urine protein levels of some biomarkers. For
example, VEGF mRNA is highly up-regulated in kidneys
after Stx2, but urine VEGF levels are higher after Stx1. It is
not possible to know how much of the elevated baboon
kidney mRNA levels are translated to protein, and, if so, how
much is released into the circulation or urine. The mechanism
for this discrepancy is not known, but a contributor may be
differential mRNA instability because of the ribosome-ajp.amjpathol.org - The American Journal of Pathology
Stx, Renal Pathology, and Chemokinesinactivating toxins. It is also relevant to note that overall time
to euthanasia was earlier for high-dose Stx1-challenged
animals at 2 to 3 days than at 4 to 5 days for animals that
received high-dose Stx2.17 This time difference may
contribute to some differences observed in tissue mRNA
levels, urine biomarkers, and development of tissue patho-
physiology. In addition, the development of HUS in the
baboons is more rapid than that in patients, which is closer to
7 to 12 days after onset of diarrhea; an enteric EHEC infection
model in the baboons is needed and is under development.
In summary, the Stx toxins from EHEC have distinct
effects on renal pathology but sufﬁcient shared effect on renal
function to result in loss of kidney function during devel-
opment of HUS. Therapeutic approaches to target only Stx2
may overlook the signiﬁcant renal injury that Stx1 can elicit,
and, although disease progression may not be as severe, long-
term kidney function may still be impaired. This is an
important consideration because 25% to 36% of surviving
patients have long-term kidney sequelae.57 Both toxins eli-
cit a strong chemotactic response in tissues, particularly
the kidneys, and this environment is likely a primary con-
tributor to toxin distribution and local inﬂammatory res-
ponses, possibly enhancing Stx effects and increasing disease
severity.
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